相似文献
1
The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer.
Int J Mol Sci. 2013 Apr 15;14(4):8213-27. doi: 10.3390/ijms14048213.
2
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
Gynecol Oncol. 2015 Apr;137(1):173-9. doi: 10.1016/j.ygyno.2015.02.003. Epub 2015 Feb 10.
3
PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway.
Int J Mol Sci. 2021 Feb 13;22(4):1882. doi: 10.3390/ijms22041882.
4
Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
Semin Cancer Biol. 2019 Dec;59:147-160. doi: 10.1016/j.semcancer.2019.05.012. Epub 2019 May 22.
5
PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer.
Biomolecules. 2018 Feb 4;8(1):7. doi: 10.3390/biom8010007.
6
CADM1 inhibits ovarian cancer cell proliferation and migration by potentially regulating the PI3K/Akt/mTOR pathway.
Biomed Pharmacother. 2020 Mar;123:109717. doi: 10.1016/j.biopha.2019.109717. Epub 2019 Dec 25.
7
MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance.
J Cancer Res Clin Oncol. 2018 Dec;144(12):2313-2318. doi: 10.1007/s00432-018-2737-y. Epub 2018 Aug 14.
8
HOTAIR/miR-326/FUT6 axis facilitates colorectal cancer progression through regulating fucosylation of CD44 via PI3K/AKT/mTOR pathway.
Biochim Biophys Acta Mol Cell Res. 2019 May;1866(5):750-760. doi: 10.1016/j.bbamcr.2019.02.004. Epub 2019 Feb 8.
9
Knockdown of Hypoxia-Inducible Factor 1α (HIF-1α) Promotes Autophagy and Inhibits Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Ovarian Cancer Cells.
Med Sci Monit. 2019 Jun 8;25:4250-4263. doi: 10.12659/MSM.915730.
10
Endoplasmic reticulum stress regulates proliferation, migration and invasion of human ovarian cancer SKOV3 cells through PI3K/AKT/mTOR signaling pathway.
Cancer Biomark. 2017 Jul 4;19(3):263-269. doi: 10.3233/CBM-160424.
引用本文的文献
1
BCAA metabolism: the Achilles' heel of ovarian cancer, polycystic ovary syndrome, and premature ovarian failure.
Front Endocrinol (Lausanne). 2025 Jul 4;16:1579477. doi: 10.3389/fendo.2025.1579477. eCollection 2025.
2
Association between urinary polycyclic aromatic hydrocarbon metabolites and premature menopause: a nationally representative cross-sectional study in the United States.
Environ Health Prev Med. 2025;30:32. doi: 10.1265/ehpm.25-00031.
3
Unravelling the role of PRKCI and key-cancer related genes in breast cancer development and metastasis.
Discov Oncol. 2025 Mar 18;16(1):350. doi: 10.1007/s12672-025-02133-x.
4
Investigation of the mechanism by which FOXJ2 inhibits proliferation, metastasis and cell cycle progression of ovarian cancer cells through the PI3K/AKT signaling pathway.
Eur J Med Res. 2025 Mar 4;30(1):152. doi: 10.1186/s40001-025-02270-7.
5
The apoptotic and anti-proliferative effects of Neosetophomone B in T-cell acute lymphoblastic leukaemia via PI3K/AKT/mTOR pathway inhibition.
Cell Prolif. 2025 Mar;58(3):e13773. doi: 10.1111/cpr.13773. Epub 2024 Nov 14.
6
Exploring the therapeutic mechanisms of Yikang decoction in polycystic ovary syndrome: an integration of GEO datasets, network pharmacology, and molecular dynamics simulations.
Front Med (Lausanne). 2024 Oct 3;11:1455964. doi: 10.3389/fmed.2024.1455964. eCollection 2024.
7
Anticancer Drug Discovery from Natural Compounds Targeting PI3K/AKT/mTOR Signaling Pathway.
Curr Med Chem. 2024 Oct 10. doi: 10.2174/0109298673325229240928040758.
8
PIM Kinase Inhibitors as Novel Promising Therapeutic Scaffolds in Cancer Therapy.
Curr Top Med Chem. 2024;24(28):2489-2508. doi: 10.2174/0115680266321659240906114742.
9
Potential of Natural Products in the Treatment of Glioma: Focus on Molecular Mechanisms.
Cell Biochem Biophys. 2024 Dec;82(4):3157-3208. doi: 10.1007/s12013-024-01447-x. Epub 2024 Aug 16.
10
Design of PI3K-mTOR Dual Inhibitors for Ovarian Cancer: Are we on the Right Track?
Curr Med Chem. 2025;32(6):1121-1143. doi: 10.2174/0109298673293028240326051835.
本文引用的文献
1
MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Oncogene. 2014 Jan 16;33(3):378-86. doi: 10.1038/onc.2012.575. Epub 2013 Jan 14.
2
MicroRNA-182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas.
J Cell Biochem. 2013 Jul;114(7):1464-73. doi: 10.1002/jcb.24488.
3
Genomic loss of tumor suppressor miRNA-204 promotes cancer cell migration and invasion by activating AKT/mTOR/Rac1 signaling and actin reorganization.
PLoS One. 2012;7(12):e52397. doi: 10.1371/journal.pone.0052397. Epub 2012 Dec 21.
4
GPR30 regulates the EGFR-Akt cascade and predicts lower survival in patients with ovarian cancer.
J Ovarian Res. 2012 Nov 19;5(1):35. doi: 10.1186/1757-2215-5-35.
5
Biomarkers for screening, diagnosis, and monitoring of ovarian cancer.
Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):1902-12. doi: 10.1158/1055-9965.EPI-12-0646. Epub 2012 Sep 7.
6
Inhibition of EGFR-AKT axis results in the suppression of ovarian tumors in vitro and in preclinical mouse model.
PLoS One. 2012;7(8):e43577. doi: 10.1371/journal.pone.0043577. Epub 2012 Aug 27.
7
sMEK1 enhances gemcitabine anti-cancer activity through inhibition of phosphorylation of Akt/mTOR.
Apoptosis. 2012 Oct;17(10):1095-103. doi: 10.1007/s10495-012-0751-0.
8
Oral administration of apigenin inhibits metastasis through AKT/P70S6K1/MMP-9 pathway in orthotopic ovarian tumor model.
Int J Mol Sci. 2012;13(6):7271-7282. doi: 10.3390/ijms13067271. Epub 2012 Jun 13.
9
MicroRNA-204 critically regulates carcinogenesis in malignant peripheral nerve sheath tumors.
Neuro Oncol. 2012 Aug;14(8):1007-17. doi: 10.1093/neuonc/nos124. Epub 2012 Jun 19.
10
Dissecting "PI3Kness": the complexity of personalized therapy for ovarian cancer.
Cancer Discov. 2012 Jan;2(1):16-8. doi: 10.1158/2159-8290.CD-11-0323.
Zotero 插件